Lawyers and Settlements
Home Page >> Xarelto Blood Thinner Side Effects >> Articles

Xarelto Articles

$28M Xarelto Verdict Against J&J and Bayer

$28M Xarelto Verdict Against J&J and Bayer December 5, 2017. By Lucy Campbell.
Philadelphia, PA: A jury has found against units of Johnson & Johnson (J&J) and Bayer AG in the fourth bellwether Xarelto (Rivaroxaban) case being heard as part of a Xarelto mass tort. The award, nearly $28 million, is the first favoring a plaintiff, in this case Lynn Hartman, who alleged she suffered a serious gastrointestinal bleed while using the blood thinning medication. The jury found that the pharmaceutical companies failed to provide adequate warnings regarding the risks for bleeding associated with Xarelto.
Read [ $28M Xarelto Verdict Against J&J and Bayer ]

Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway

Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway November 17, 2017. By Gordon Gibb.
Philadelphia, PA: The first trial in the large Xarelto mass tort in Philadelphia is underway, with damning testimony already on the record from a former commissioner of the US Food and Drug Administration (FDA). While three bellwether lawsuits have already been tried in multidistrict litigation in Louisiana, the Xarelto lawsuit brought by plaintiff Lynn Hartman is the first of some 1,500 cases housed in the Philadelphia mass tort to face a jury.
Read [ Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway ]

First Xarelto Trial Stalled Over Allegations of Witness Tampering

First Xarelto Trial Stalled Over Allegations of Witness Tampering November 6, 2017. By Lucy Campbell.
Philadelphia, PA: Allegations of witness tampering have stalled the beginning of the Xarelto litigation. The first Xarelto trail was set to being Monday, November 6, but instead got sidelined by attempts to determine the significance of a meeting between a key witness, Dr. Timothy Aldridge, the plaintiff’s treating physician, and a Janssen sales representative.
Read [ First Xarelto Trial Stalled Over Allegations of Witness Tampering ]

Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues

Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues August 5, 2017. By Gordon Gibb.
Washington, DC: Towards the end of May plaintiffs embroiled in some 18,000 Xarelto lawsuits consolidated in multidistrict litigation were pushing back against a move by defendants Janssen Pharmaceuticals Inc. (Janssen, a division of Johnson & Johnson) and Bayer HealthCare Pharmaceuticals Inc. (Bayer) to escape claims that relied on allegations plaintiffs had previously dropped.
Read [ Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues ]

Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third

Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third July 8, 2017. By Gordon Gibb.
New Orleans, LA: The second bellwether Xarelto lawsuit in multidistrict litigation over allegations of Xarelto bleedout in association with the new age blood thinner has gone, like the first, to the defendant. While this may prove disappointing to litigants alleging the anticoagulant is unsafe, there are still two more bellwether trials to roll out later this year, with some 15,000 cases in the federal multidistrict litigation pipeline housed in New Orleans. Additional cases are percolating at the state level in Philadelphia.
Read [ Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third ]

Forecasting the Xarelto Bellwether Trials

Forecasting the Xarelto Bellwether Trials June 12, 2017. By Gordon Gibb.
New Orleans, LA: There is speculation that a bellwether Xarelto lawsuit, currently underway in the state of Louisiana, may end as the first bellwether concluded; with a verdict for the defense. However, legal commentator Tighe Wilhelmy of Velawcity notes that Louisiana’s ‘Learned Intermediary Doctrine Defense’ may not necessarily apply going forward to cases whose original jurisdictions fall outside the state of Louisiana.
Read [ Forecasting the Xarelto Bellwether Trials ]

Claims against Xarelto Due to Be Tested in Court Again

Claims against Xarelto Due to Be Tested in Court Again May 28, 2017. By Brenda Craig.
New Orleans, LA On May 30, 2017, a courtroom in New Orleans will hear testimony for another major bell weather case involving the controversial blood thinner drug Xarelto and the late Sharyn Orr from Kenner, Louisiana.
Read [ Claims against Xarelto Due to Be Tested in Court Again ]

First Xarelto Bellwether Trial Goes to the Defense

First Xarelto Bellwether Trial Goes to the Defense May 12, 2017. By Gordon Gibb.
New Orleans, LA: The long-anticipated first bellwether trial in multidistrict litigation for Xarelto side effects has gone to the defendants. Plaintiff Joseph Boudreaux’s trial commenced April 24 and all eyes were on the litigation as an indicator as to how other bellwether trials might go.
Read [ First Xarelto Bellwether Trial Goes to the Defense ]

Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding

Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding April 11, 2017. By Gordon Gibb.
Philadelphia, PA: As the Philadelphia Xarelto mass tort moves closer towards the bellwether trial stage, Xarelto principles Bayer AG and Janssen Pharmaceuticals have signaled that they want to know the identity of any third-party funders associated with Xarleto bleeding issue lawsuits. In other words, the defendants want to know how plaintiffs are funded.
Read [ Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding ]

Plaintiffs Looking for a Slam Dunk in First Xarelto Bellwether Trial This Month

Plaintiffs Looking for a Slam Dunk in First Xarelto Bellwether Trial This Month March 1, 2017. By Gordon Gibb.
New Orleans, LA: It could be mere co-incidence, but on the eve of the National Basketball Association (NBA) All Star Game that served to delay Xarelto bellwether trials by a month, the manufacturers of Xarelto chose to highlight an aging NBA all-star player who expounds upon the virtues of rivaroxaban (Xarelto) and professes to use it himself. As such, a visit to the official Xarelto website showcases the former All-American player, rather than the potential for a Xarelto bleeding issue.
Read [ Plaintiffs Looking for a Slam Dunk in First Xarelto Bellwether Trial This Month ]

Page: 1  2     Next»